Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -109.7%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $16M | $49M | $70M | $59M | $121M | $159M | — |
| Enterprise Value | $4M | $37M | $67M | $48M | $107M | $139M | — |
| P/E Ratio → | -1.58 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.15 | 4.18 | 18.49 | 5.56 | 8.06 | 7.44 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -109.7% | -109.7% | -113.8% | -91.4% | -37.4% | -249.9% | -6.2% |
| ROA | -104.6% | -104.6% | -104.2% | -86.1% | -36.7% | -245.1% | -5.8% |
| ROIC | -1848.6% | -1848.6% | -17243.8% | — | -526.9% | -385.3% | — |
| ROCE | -117.2% | -117.2% | -115.3% | -91.8% | -37.5% | -29.8% | -6.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.07 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | -0.81 | -1.06 | -0.97 | -0.93 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -21.21 | -21.21 | -53.23 | — | — | -2569.98 | -134.80 |
Net cash position: cash ($12M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 53.36 | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 | 13.53 |
| Quick Ratio | 53.36 | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 | 13.53 |
| Cash Ratio | 51.87 | 51.87 | 11.87 | 10.52 | 28.39 | 82.71 | 13.51 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $34M | $26M | $25M | $23M | $23M | $24M |
Clinical trial funding exhaustion
Based on reported figures, Anebulo trades at a price-to-book ratio of 1.15, which reflects a significant discount compared to peers like ATAI and MNMD, suggesting that the market is heavily discounting the company's intangible clinical assets due to the binary nature of its lead candidate's regulatory success.
The current valuation appears to be driven more by the company's remaining cash runway than by any long-term earnings potential, which is typical for pre-revenue biotech firms. Investors should note that the lack of a forward P/E or EV/EBITDA multiple underscores the absence of a commercial foundation, making traditional valuation metrics largely irrelevant until clinical milestones are achieved.
According to recent SEC filings, Anebulo's ROIC has remained consistently negative, reaching -16.4% in 2025Q4, which highlights the company's inability to generate returns on invested capital while it continues to prioritize high-cost clinical development over immediate profitability or operational efficiency.
The persistent negative return on capital is a structural reality for a single-asset firm that has yet to reach commercialization. This trend suggests that capital is being consumed at a rate that far outpaces the potential value creation of the current pipeline, warranting close monitoring of how management allocates remaining funds.
As reported in financial statements, Anebulo's current ratio has fluctuated significantly, dropping from a peak of 25.29 in 2025Q3 to 16.71 in 2026Q2, indicating that while the company maintains a high liquidity position, its cash reserves are being rapidly depleted by ongoing clinical trial expenditures.
The high current ratio is somewhat misleading, as it reflects the absence of significant short-term liabilities rather than operational strength. Investors should interpret this liquidity as a finite runway that necessitates a strategic decision regarding future financing before the company reaches a critical cash-exhaustion point.
Based on the provided data, the most commonly misapplied metric for Anebulo is the net profit margin, which is frequently cited by automated screeners but obscures the reality that the company is a pre-revenue entity where losses are a planned outcome of clinical development.
Using net margin to evaluate Anebulo is fundamentally flawed because it treats R&D expenses as operational inefficiencies rather than the core investment activity of the business. Analysts should instead focus on the cash burn rate and the time-to-milestone, as these metrics provide a more accurate assessment of the company's viability than traditional profitability ratios.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANEB stock.
Anebulo Pharmaceuticals, Inc.'s current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Anebulo Pharmaceuticals, Inc.'s return on equity (ROE) is -109.7%. The historical average is -101.4%.
Based on historical data, Anebulo Pharmaceuticals, Inc. is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.